Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Moderna 0.145, CSL 3.6525.
* CSL reports semi-annually. Values are evenly split across both quarters within each half.
Moderna vs CSL: Revenue Comparison
Moderna (MRNA) and CSL (CSL.AX) are peers in Vaccines. Moderna reported revenue of $145M as of Q2 2026, compared with $7.3B for CSL. CSL leads on revenue.
Moderna's gross margin is 35.9% versus 44.4% for CSL. Moderna's net margin is -539.3% versus -40.2% for CSL.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Moderna, CSL.| Metric | Moderna | CSL |
|---|---|---|
| Market Cap | - | - |
| Revenue | $145.00M | $7.30B |
| Cost of Revenue | $93.00M | $4.06B |
| Gross Profit | $52.00M | $3.24B |
| Operating Income | $-815.00M | $1.39B |
| Net Income | $-782.00M | $-2.94B |
| R&D Expense | $651.00M | $614.00M |
| Earnings Per Share | -$1.96 | -$6.14 |
| Gross Margin | 35.9% | 44.4% |
| Operating Margin | -562.1% | 19.0% |
| Net Profit Margin | -539.3% | -40.2% |
| Free Cash Flow | $-563.00M | $1.76B |
| Cumulative Free Cash Flow | $7.37B | $21.56B |
| Operating Cash Flow | $-526.00M | $2.09B |
| Cash & Equivalents | $1.72B | $1.51B |